IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.939
AS - Asia 6.043
EU - Europa 1.993
SA - Sud America 1.449
AF - Africa 357
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.703
SG - Singapore 3.640
BR - Brasile 1.179
CN - Cina 926
VN - Vietnam 736
FI - Finlandia 413
IE - Irlanda 276
NG - Nigeria 221
DE - Germania 215
IT - Italia 202
GB - Regno Unito 181
FR - Francia 180
CA - Canada 141
HK - Hong Kong 137
NL - Olanda 112
IN - India 110
SE - Svezia 104
AR - Argentina 101
TR - Turchia 67
BD - Bangladesh 66
RU - Federazione Russa 58
MX - Messico 55
IQ - Iraq 54
EC - Ecuador 50
ID - Indonesia 45
ES - Italia 42
IL - Israele 42
UA - Ucraina 42
ZA - Sudafrica 38
BE - Belgio 37
JP - Giappone 32
CO - Colombia 31
EG - Egitto 26
PY - Paraguay 24
CL - Cile 23
SA - Arabia Saudita 22
DZ - Algeria 21
PK - Pakistan 21
AU - Australia 20
CZ - Repubblica Ceca 19
PL - Polonia 19
VE - Venezuela 19
KZ - Kazakistan 14
MA - Marocco 14
UZ - Uzbekistan 14
IR - Iran 13
LT - Lituania 13
KE - Kenya 12
RO - Romania 12
AE - Emirati Arabi Uniti 11
PE - Perù 11
PH - Filippine 11
PT - Portogallo 11
AZ - Azerbaigian 10
KR - Corea 10
MY - Malesia 10
NP - Nepal 9
UY - Uruguay 8
JM - Giamaica 7
SK - Slovacchia (Repubblica Slovacca) 7
TN - Tunisia 7
AL - Albania 6
AT - Austria 6
GR - Grecia 6
HN - Honduras 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
JO - Giordania 5
MD - Moldavia 5
QA - Qatar 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BB - Barbados 4
BY - Bielorussia 4
GE - Georgia 4
NO - Norvegia 4
SN - Senegal 4
BN - Brunei Darussalam 3
CH - Svizzera 3
ET - Etiopia 3
EU - Europa 3
KH - Cambogia 3
KW - Kuwait 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
BF - Burkina Faso 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
KG - Kirghizistan 2
LV - Lettonia 2
OM - Oman 2
SV - El Salvador 2
TW - Taiwan 2
Totale 19.792
Salva come PNG Salva come JPEG
Città #
Singapore 1.721
Wilmington 1.549
Chandler 1.238
The Dalles 601
San Mateo 587
Ashburn 576
Dallas 506
Ann Arbor 435
Shanghai 422
Helsinki 410
Leawood 286
Lawrence 271
Princeton 271
Dublin 270
Ho Chi Minh City 262
San Jose 253
Boardman 234
Benin City 220
New York 220
Beijing 202
Hanoi 165
Woodbridge 152
Fairfield 151
Paris 148
Hong Kong 132
São Paulo 113
Amsterdam 91
Toronto 91
Los Angeles 77
Santa Clara 77
London 74
Milan 58
Buffalo 55
Rio de Janeiro 51
Norwalk 47
Seattle 44
Orem 41
Kocaeli 40
Columbus 39
Haiphong 34
Phoenix 34
Brussels 33
Council Bluffs 32
Monmouth Junction 28
San Diego 27
Brasília 26
Redwood City 26
Da Nang 22
Baghdad 21
Curitiba 21
Guayaquil 21
Munich 20
Frankfurt am Main 19
Belo Horizonte 18
Chennai 18
Johannesburg 18
Tokyo 18
Biên Hòa 17
Campinas 17
Chicago 17
Pune 17
Abbiategrasso 16
Cambridge 16
Montreal 16
Falkenstein 15
Brno 14
Hải Dương 14
Porto Alegre 14
Rome 14
Cairo 13
Houston 13
Ninh Bình 13
Warsaw 13
Erbil 12
Guarulhos 12
Nairobi 12
Can Tho 11
Dhaka 11
Goiânia 11
Jakarta 11
Medellín 11
Quito 11
Tashkent 11
Thái Bình 11
Brooklyn 10
Cape Town 10
Istanbul 10
Manchester 10
Mexico City 10
Moscow 10
Phủ Lý 10
Sacramento 10
Santo André 10
Baku 9
Boston 9
Charlotte 9
Des Moines 9
Lisbon 9
Mumbai 9
Salvador 9
Totale 13.132
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 373
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 148
Adalimumab in ulcerative colitis: hypes and hopes 142
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 131
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 126
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 123
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 122
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 121
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 118
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 118
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 117
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 115
Risk of postoperative recurrence and postoperative management of Crohn's disease 110
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 109
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 108
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 106
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 106
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 103
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 103
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 101
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 2. IBD scores and general principles and technical aspects 101
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 100
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 100
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 99
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 99
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 99
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 98
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 97
Perception of reproductive health in women with inflammatory bowel disease 97
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 96
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment 95
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 95
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 95
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 93
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 93
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 93
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 93
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 93
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 92
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 92
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 91
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 91
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 90
Are Surgical Rates Decreasing in the Biological Era In IBD? 90
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 89
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 88
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 88
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 88
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 86
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 86
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 85
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 85
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease 85
Adalimumab for the treatment of pediatric Crohn's disease 84
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 84
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 84
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 84
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 84
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 83
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 82
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 81
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 81
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease 81
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 81
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 80
JAK inhibitors: Novel developments in management of ulcerative colitis 80
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 80
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 80
Emerging therapeutic targets and strategies in Crohn's disease 79
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 79
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 79
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 78
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biologics 78
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 78
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 76
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients 76
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 76
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy 76
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study 75
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 75
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 75
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease 75
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges 75
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 74
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 74
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience 74
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 73
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 73
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 73
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 73
Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation (ECCO) position paper 73
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 73
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 73
Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey 72
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 72
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 72
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 72
Videocapsule endoscopy in portal hypertension: Seek till you find 72
Safety of a (H1N1)V Vaccine in patients with inflammatory bowel disease treated with immunomodulators and biologicals 72
The learning curve for using intestinal ultrasonography 71
Totale 9.277
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021328 0 0 0 0 0 0 0 0 0 0 0 328
2021/20221.508 99 15 65 304 12 8 64 196 152 203 308 82
2022/20233.327 612 152 386 349 205 279 16 253 541 321 168 45
2023/20241.918 202 148 382 92 56 252 101 117 34 41 167 326
2024/20252.695 60 61 25 55 29 323 127 300 349 738 294 334
2025/20267.653 1.036 547 720 1.032 286 249 1.946 440 406 448 266 277
Totale 20.077